Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Time to Sell?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $16.00, but opened at $15.40. Ascentage Pharma Group International shares last traded at $15.5150, with a volume of 1,471 shares trading hands.

Analyst Ratings Changes

Several research firms recently commented on AAPG. BTIG Research reaffirmed a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Finally, B. Riley Financial assumed coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $46.43.

Get Ascentage Pharma Group International alerts:

Get Our Latest Report on Ascentage Pharma Group International

Ascentage Pharma Group International Price Performance

The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18. The business’s fifty day simple moving average is $18.02 and its two-hundred day simple moving average is $20.32.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $22.24 million for the quarter. As a group, equities analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current year.

Ascentage Pharma Group International Company Profile

(Get Free Report)

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.

Read More

• Five stocks we like better than Ascentage Pharma Group International
• Micron’s AI Memory Boom Could Send Shares 100% Higher
• Apple Stock Surges After Its Biggest Product Launch in Years—Can It Last?
• The Ultimate Cyber Shield: CrowdStrike Rises Past $235
• Palantir Just Told Wall Street Where AI Infrastructure Is Headed

Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.